Source: Taiwan United Daily
United Daily Black and White Collection
This year, Taiwan's public influenza vaccine decision, in addition to the years of Guoguang, Sanofi, and Toyo, there are also "strange familiar faces", and high -end high -end is also marked.Different from the "price bids" in previous years, this year's "most favorable label" was changed.Everyone must want to ask: Who is the most beneficial to the label?
The magic of high -end is not the effect of vaccine, but keeps precedent for it in the government.The R & D of coronary vaccine, the first "immune bridge" of the Ministry of Health and Welfare, eliminates the third phase of clinical trials.The emergency authorization of the fast screen test agent, the applicants, the largest shareholders of the high -end "Fu Yida" again.Public -funded influenza was the most favorable label. The high -end flying on the branches again.
Public influenza vaccines are not everyone who can fight, and should have a choice.Guoguang is the only self -produced in Taiwan. Sanofi and Toyo are available for six months of infants and young children. Toyo is the only "non -egg embryo" vaccine, with its own uniqueness.However, the high -end imported Korean vaccine is similar to the Guoguang vaccine; but the reduction of purchases is the vaccine of Toyo agents.Such a procurement logic is dumbfounded.
Maybe logic is not difficult.As the "Guardian Mountain" of the Cai government, high -end crown vaccines cannot obtain international certification, and fell over the altar overnight, resulting in zero revenue for three months.The Ministry of Health and Welfare is based on pity, and the purchase of influenza vaccines its agent can also be regarded as "rainy" to help it get rid of the zero dilemma.The so -called most favorable standard refers to high -end, not inoculating.
Although "benefits" may not be "Tuli", the Ministry of Health and Welfare has repeatedly "preceding" for a single enterprise. If it is not a high -end Tuli, can it be said that it is loved the people?
